Degeneration Articular Cartilage Knee
Conditions
Keywords
human umbilical cord blood-derived mesenchymal stem cells, MSC, cartilage lesion, cartilage defect, degenerative arthritis, stem cell implantation
Brief summary
The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Detailed description
Conventional treatment modalities have not been able to provide complete and sustained resolution of symptoms following damage to the articular cartilage. Despite the numerous techniques available today, complete healing of damaged or defective cartilage or consistent reproduction of normal hyaline cartilage does not occur, and continuous drug administration or secondary surgeries are common. Research in mesenchymal stem cells has had a rapid acceleration over the past decade and MSC-based therapy has become one of the objects of investigation for a new branch of medicine termed regenerative medicine. This emerging technology shows great promise for producing transplantable cartilage constructs to restore the function of degenerated joints. CARTISTEM®, a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, is intended to be used as a single-dose cellular therapeutic agent for cartilage regeneration in human subjects with cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Interventions
BIOLOGICALCARTISTEM®
Sponsors
Medipost, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with an intended- to- treat single focal, full-thickness cartilage defect (ICRS \[International Cartilage Repair Society\] Grade 3 or 4) of the knee as a result of ageing, trauma, or degenerative diseases. * Age ≥ 18 years old * Size of the articular cartilage lesion is ≥ 2 cm2 * Swelling, tenderness and active range of motion ≤ Grade II * Joint pain : 20-mm - 60-mm on VAS (Visual Analog Scale) at the time of Screening * Appropriate blood coagulation, kidney and liver function laboratory parameters: PT(INR) \< 1.5, APTT \<1.5×control Creatinine ≤ 2.0 mg/dL Albumin ≤ trace in urine dipstick test Bilirubin ≤ 2.0 mg/dL, AST/ALT ≤ 100 IU/L * Ligament instability ≤ Grade II * Lower extremity alignment within 5 degrees of the neutral weight bearing axis * No meniscal surgery within the past 3 months and more than 5mm of meniscal rim remaining * Ability and willingness to fully participate in the post-operative rehabilitation program * Subject is informed of the investigational nature of this study, voluntarily agrees to participate in the study, and signs an IRBapproved informed consent prior to performing any of the screening procedures * Body Mass Index (BMI) ≤ 35 kg/m2
Exclusion criteria
* Patients who have been treated previously and are asymptomatic * Avascular necrosis/ osteonecrosis * Autoimmune or inflammatory joint disease * History of infection within the past 6 weeks * Surgery or radiation therapy within the past 6 weeks * Serious medical co-morbidities, which would otherwise contraindicate surgery, as determined by the investigator * Currently pregnant or nursing * Psychotic diseases, epilepsy, or any history of such diseases * Current abuse of alcohol (\> 10 drinks weekly) and/or regular exposure to other substances of abuse, currently an active smoker * Chronic inflammatory articular diseases such as rheumatoid arthritis * Enrolled in any other clinical trials within the past 4 weeks * Administered immunosuppressants such as Cyclosporin A or azathioprine within the past 6 weeks * Ligament instability \> Grade II * Uncorrected significant lower extremity malalignment (i.e. \> 5 degrees) * (sub-) Total meniscectomy (\<5mm rim remaining) * Corticosteroid or viscosupplementation injection to the affected knee in the past 3 months * Principal investigator considers inappropriate for the clinical trial due to any reasons other than those listed above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| IKDC Score | 12 months | Subjects underwent a self-assessment of knee function using the IKDC (International Knee Documentation Committee Assessment)subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Months 12 after IP administration in an exploratory fashion. The IKDC score from the Month 12 visit was used as a primary indicator of the post operative change. The outcome was presented with the post-operative change amount from the baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| VAS | 24 months | Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline. 100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain. |
| Lysholm Score | 24 months | The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs. The possible score ranges from 0 to 100, where 100 = no symptoms or disability. Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (≤64). Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline. |
| KOOS Score | 24 months | The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL). Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from "never/not at all" to "always/extremely." The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems. Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration. The outcome was presented with the post-operative change amount at Month 24 from the baseline. |
| IKDC Score | 24 months | Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion. The outcome was presented with the post-operative change amount at Month 24 from the baseline. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORBrian J Cole, MD
Cartilage Restoration Center, Rush University Medical Center
PRINCIPAL_INVESTIGATORAndreas H Gomoll, MD
Cartilage Repair Center, Brigham and Women's Hospital
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose A Cohort Drug name and ingredients: CARTISTEM \[allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate\] Dosage: Administer 0.5 mL of the combination product per cm\^2 of the cartilage defect
Cartilage defect size range: 2 to 5 cm2 (Dose A)
CARTISTEM® | 6 |
| Dose B Cohort Drug name and ingredients: CARTISTEM \[allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate\] Dosage: Administer 0.5 mL of the combination product per cm\^2 of the cartilage defect
Cartilage defect size range: above 5 cm2 (Dose B)
CARTISTEM® | 6 |
| Total | 12 |
Baseline characteristics
| Characteristic | Dose A Cohort | Dose B Cohort | Total |
|---|---|---|---|
| Age, Continuous | 36.3 years STANDARD_DEVIATION 8.2 | 39.7 years STANDARD_DEVIATION 8 | 38.0 years STANDARD_DEVIATION 7.9 |
| Body mass index | 28.6 kg/m^2 STANDARD_DEVIATION 4.1 | 26.6 kg/m^2 STANDARD_DEVIATION 4.5 | 27.6 kg/m^2 STANDARD_DEVIATION 4.3 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants | 6 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 5 Participants | 10 Participants |
| Region of Enrollment United States | 6 participants | 6 participants | 12 participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Male | 5 Participants | 5 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 6 / 6 | 6 / 6 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 |
Outcome results
Primary
IKDC Score
Subjects underwent a self-assessment of knee function using the IKDC (International Knee Documentation Committee Assessment)subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Months 12 after IP administration in an exploratory fashion. The IKDC score from the Month 12 visit was used as a primary indicator of the post operative change. The outcome was presented with the post-operative change amount from the baseline.
Time frame: 12 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose A Cohort | IKDC Score | 32.0 score on a scale | Standard Deviation 27.7 |
| Dose B Cohort | IKDC Score | 25.5 score on a scale | Standard Deviation 18.9 |
Secondary
IKDC Score
Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion. The outcome was presented with the post-operative change amount at Month 24 from the baseline.
Time frame: 24 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Dose A Cohort | IKDC Score | 41.2 score on a scale | Standard Deviation 25.8 |
| Dose B Cohort | IKDC Score | 27.5 score on a scale | Standard Deviation 20.9 |
Secondary
KOOS Score
The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL). Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from never/not at all to always/extremely. The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems. Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration. The outcome was presented with the post-operative change amount at Month 24 from the baseline.
Time frame: 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dose A Cohort | KOOS Score | PAIN (24 MONTHS) | 23.6 score on a scale | Standard Deviation 24.3 |
| Dose A Cohort | KOOS Score | SPORTS (24 MONTHS) | 39.2 score on a scale | Standard Deviation 37.2 |
| Dose A Cohort | KOOS Score | QOL (24 MONTHS) | 50.0 score on a scale | Standard Deviation 36.4 |
| Dose A Cohort | KOOS Score | SYMPTOM (24 MONTHS) | 24.4 score on a scale | Standard Deviation 19.9 |
| Dose A Cohort | KOOS Score | ADL (24 MONTHS) | 28.2 score on a scale | Standard Deviation 25.7 |
| Dose B Cohort | KOOS Score | SYMPTOM (24 MONTHS) | 8.3 score on a scale | Standard Deviation 12.3 |
| Dose B Cohort | KOOS Score | ADL (24 MONTHS) | 12.3 score on a scale | Standard Deviation 19.2 |
| Dose B Cohort | KOOS Score | PAIN (24 MONTHS) | 15.8 score on a scale | Standard Deviation 13.1 |
| Dose B Cohort | KOOS Score | QOL (24 MONTHS) | 19.8 score on a scale | Standard Deviation 24.2 |
| Dose B Cohort | KOOS Score | SPORTS (24 MONTHS) | 36.7 score on a scale | Standard Deviation 31.9 |
Secondary
Lysholm Score
The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs. The possible score ranges from 0 to 100, where 100 = no symptoms or disability. Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (≤64). Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.
Time frame: 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dose A Cohort | Lysholm Score | 12 MONTHS | 26.7 score on a scale | Standard Deviation 20.5 |
| Dose A Cohort | Lysholm Score | 24 MONTHS | 32.0 score on a scale | Standard Deviation 20.9 |
| Dose B Cohort | Lysholm Score | 12 MONTHS | 22.5 score on a scale | Standard Deviation 18.3 |
| Dose B Cohort | Lysholm Score | 24 MONTHS | 10.2 score on a scale | Standard Deviation 13 |
Secondary
VAS
Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline. 100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain.
Time frame: 24 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dose A Cohort | VAS | 12 MONTHS | -23.8 score on a scale | Standard Deviation 22.9 |
| Dose A Cohort | VAS | 24 MONTHS | -31.7 score on a scale | Standard Deviation 18 |
| Dose B Cohort | VAS | 12 MONTHS | -12.5 score on a scale | Standard Deviation 31.5 |
| Dose B Cohort | VAS | 24 MONTHS | -11.3 score on a scale | Standard Deviation 30.2 |